A142760 Stock Overview
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MOA Life Plus Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,300.00 |
| 52 Week High | ₩4,500.00 |
| 52 Week Low | ₩1,500.00 |
| Beta | 0.79 |
| 1 Month Change | 29.16% |
| 3 Month Change | 97.60% |
| 1 Year Change | -23.26% |
| 3 Year Change | -45.90% |
| 5 Year Change | -72.15% |
| Change since IPO | -76.76% |
Recent News & Updates
Shareholder Returns
| A142760 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -13.8% | 3.5% | 2.1% |
| 1Y | -23.3% | 7.0% | 6.6% |
Return vs Industry: A142760 underperformed the KR Biotechs industry which returned 7% over the past year.
Return vs Market: A142760 underperformed the KR Market which returned 6.6% over the past year.
Price Volatility
| A142760 volatility | |
|---|---|
| A142760 Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A142760's share price has been volatile over the past 3 months.
Volatility Over Time: A142760's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 45 | Andy Chul | www.moalifeplus.com |
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug.
MOA Life Plus Co. Ltd. Fundamentals Summary
| A142760 fundamental statistics | |
|---|---|
| Market cap | ₩124.52b |
| Earnings (TTM) | -₩6.20b |
| Revenue (TTM) | ₩18.25b |
6.8x
P/S Ratio-20.1x
P/E RatioIs A142760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A142760 income statement (TTM) | |
|---|---|
| Revenue | ₩18.25b |
| Cost of Revenue | ₩12.70b |
| Gross Profit | ₩5.54b |
| Other Expenses | ₩11.75b |
| Earnings | -₩6.20b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -164.42 |
| Gross Margin | 30.37% |
| Net Profit Margin | -34.00% |
| Debt/Equity Ratio | 16.5% |
How did A142760 perform over the long term?
See historical performance and comparison